Literature DB >> 16311883

Serum hyaluronidase aberrations in metabolic and morphogenetic disorders.

Berta Fiszer-Szafarz1, Barbara Czartoryska, Anna Tylki-Szymanska.   

Abstract

Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. Levels of both beta-N-acetylglucosaminidase and beta-glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0-3.2 units/microL vs 6(+/- 1 SE) units/microL). These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. No patient totally lacked serum Hyal-1 activity. Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311883     DOI: 10.1007/s10719-005-1390-2

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   3.009


  36 in total

Review 1.  Hyaluronan: fundamental principles and applications in cancer.

Authors:  B Delpech; N Girard; P Bertrand; M N Courel; C Chauzy; A Delpech
Journal:  J Intern Med       Date:  1997-07       Impact factor: 8.989

Review 2.  Enzymic pathways of hyaluronan catabolism.

Authors:  L Rodén; P Campbell; J R Fraser; T C Laurent; H Pertoft; J N Thompson
Journal:  Ciba Found Symp       Date:  1989

Review 3.  Inhibitors of the hyaluronidases.

Authors:  Kazuhiro Mio; Robert Stern
Journal:  Matrix Biol       Date:  2002-01       Impact factor: 11.583

4.  Demonstration of a new hyaluronidase inhibitor in serum of cancer patients.

Authors:  B Fiszer-Szafarz
Journal:  Proc Soc Exp Biol Med       Date:  1968-10

5.  Hyaluronidase polymorphism detected by polyacrylamide gel electrophoresis. Application to hyaluronidases from bacteria, slime molds, bee and snake venoms, bovine testes, rat liver lysosomes, and human serum.

Authors:  B Fiszer-Szafarz
Journal:  Anal Biochem       Date:  1984-11-15       Impact factor: 3.365

6.  Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31.

Authors:  A B Csóka; S W Scherer; R Stern
Journal:  Genomics       Date:  1999-09-15       Impact factor: 5.736

Review 7.  Devising a pathway for hyaluronan catabolism: are we there yet?

Authors:  Robert Stern
Journal:  Glycobiology       Date:  2003-09-26       Impact factor: 4.313

Review 8.  Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix.

Authors:  A Bignami; M Hosley; D Dahl
Journal:  Anat Embryol (Berl)       Date:  1993-11

9.  Temporal and spatial analysis of hyaluronidase activity during development of the embryonic chick limb bud.

Authors:  W M Kulyk; R A Kosher
Journal:  Dev Biol       Date:  1987-04       Impact factor: 3.582

10.  Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood.

Authors:  J P Kampine; R O Brady; J N Kanfer; M Feld; D Shapiro
Journal:  Science       Date:  1967-01-06       Impact factor: 47.728

View more
  3 in total

1.  Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis.

Authors:  Ertugrul Kiykim; Kenan Barut; Mehmet Serif Cansever; Cigdem Aktuglu Zeybek; Tanyel Zubarioglu; Ahmet Aydin; Ozgur Kasapcopur
Journal:  JIMD Rep       Date:  2015-06-30

Review 2.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

3.  Fabrication of an rhBMP-2 loaded porous β-TCP microsphere-hyaluronic acid-based powder gel composite and evaluation of implant osseointegration.

Authors:  Jae Hyup Lee; Jungju Kim; Hae-Ri Baek; Kyung Mee Lee; Jun-Hyuk Seo; Hyun-Kyung Lee; A-Young Lee; Guang Bin Zheng; Bong-Soon Chang; Choon-Ki Lee
Journal:  J Mater Sci Mater Med       Date:  2014-06-14       Impact factor: 3.896

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.